Thomas, D., Henshaw, R., Skubitz, K., Chawla, S., Staddon, A., Blay, J.Y., et al. (2010) Denosumab in Patients with Giant-Cell Tumour of Bone: An Open-Label, Phase 2 Study. The Lancet Oncology, 11, 275-280.
https://doi.org/10.1016/S1470-2045(10)70010-3

has been cited by the following article:

• TITLE: Giant Cell Tumour of the Skull Base Treated with Surgery, Stereotactic Radiosurgery and Denosumab: Case Report and Review of Literature

  AUTHORS: Jorge H. Guajardo, Cuauhtemoc de la Peña, Maria F. Gonzalez, Cesar Gonzalez, Carlos Cuilty, Horacio Decanini

  KEYWORDS: Giant Cell Tumour, Skull Base, Stereotactic Radiosurgery, Denosumab

  JOURNAL NAME: Open Access Library Journal, Vol.4 No.5, May 16, 2017

  ABSTRACT: Giant cell tumours (GCT) of the skull base account for approximately 1% of all GTC of the bone. Despite being considered as a benign neoplasm, they are locally aggressive with high recurrence rates after incomplete surgery. Due to the small number of cases reported in skull base, standardized treatment remains unclear. Even with new surgical techniques, a complete resection in skull base tumours is not always possible without functional compromise. Therefore, adjuvant therapy is essential to enhance local control and quality of life. We described a case treated successfully with primary surgery followed by Cyberknife stereotactic radiosurgery (SRS) and denosumab with a 48-month follow-up. To the best of our knowledge, the usage of combined therapy, SRS and denosumab, in skull base GCT has not been previously described.